JJR CAPITAL ANNOUNCES PROPOSED QUALIFYING TRANSACTION OF J5 ACQUISITION CORP. WITH TRIMEL BIOPHARMA HOLDINGS INC.

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TSX VENTURE EXCHANGE:  JV.P 

TORONTO, Feb. 15 /CNW/ - J5 Acquisition Corp. ("J5") (TSXV: JV.P), a capital pool company, announced today that it has entered into a letter of intent dated February 14, 2011 with Trimel BioPharma Holdings Inc. ("Trimel") to complete a going public transaction for Trimel (the "Proposed Transaction") by way of a business combination or similar transaction with J5 or a subsidiary thereof.

Trimel is a privately held pharmaceutical company incorporated under the laws of Barbados.  Trimel is focused on improving the utility of known and successfully marketed pharmaceutical compounds by employing 21st century dosing technologies that are specifically designed to avoid first pass metabolism. These Localized Dosing Technologies ("LDT") allow Trimel to precisely target the distribution of medications reducing side effects and improving patient outcomes over existing marketed products.

In conjunction with the Proposed Transaction, Trimel intends to complete a concurrent private placement and it is anticipated that J5 will complete a capital restructuring including a consolidation of its share capital.  If the Proposed Transaction is completed, it is anticipated that J5 will change its name to "Trimel BioPharma Corporation" or a similar name. 

If completed, the Proposed Transaction will constitute J5's Qualifying Transaction (as defined in Policy 2.4 of the TSX Venture Exchange Corporate Finance Manual).  A comprehensive press release with further particulars relating to the Proposed Transaction will follow in accordance with the policies of the TSX Venture Exchange (the "Exchange").

Completion of the Proposed Transaction is subject to a number of conditions including, but not limited to, the receipt of regulatory approvals, the negotiation and execution of definitive transaction documents, completion of satisfactory due diligence, and acceptance of the Exchange.

Investors are cautioned that, except as disclosed in the management information circular or prospectus to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon.  Trading in securities of a capital pool company should be considered highly speculative.

The Exchange has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release.  Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction.

ANY SECURITIES REFERRED TO HEREIN WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE "1933 ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO A U.S. PERSON IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE 1933 ACT.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.  ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW.

Notice on forward-looking statements:

This release includes forward-looking statements regarding J5, Trimel and their respective businesses.  Such statements are based on management's current expectations.  The forward-looking events and circumstances discussed in this release, including completion of the Proposed Transaction between J5 and Trimel, may not occur and actual operating results could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the pharmaceutical industry, regulatory risks, and risks associated with growth and competition.  No forward-looking statement can be guaranteed.  Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and J5 undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information regarding Trimel BioPharma please contact Kenneth Howling, Chief Financial Officer at 416-679-0536 or investor.relations@trimelbiopharma.com.

J5 is a capital pool company governed by the policies of the Exchange.  J5's principal business is the identification and evaluation of assets or businesses with a view to completing a Qualifying Transaction.

SOURCE J5 Acquisition Corp.

For further information:

please contact Ronald D. Schmeichel, Chief Executive Officer of J5 at 416-972-6294.

Profil de l'entreprise

J5 Acquisition Corp.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.